覆膜自膨式金属支架治疗恶性肝门部胆道梗阻的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析共纳入7项研究,评估覆膜自膨式金属支架(CSEMS)治疗恶性肝门部胆道梗阻(MHBO)的疗效与安全性。汇总技术成功率为96.7%(95%CI 92.6-98.6;I²=0%),临床成功率为91.6%(95%CI 86.1-95.0;I²=0%),总体不良事件发生率为16.6%(95%CI 11.2-23.9;I²=24%),支架移位和复发性胆道梗阻(RBO)分别见于8.9%和49.6%的病例,中位RBO时间为142天。作者结论认为CSEMS在MHBO管理中显示高效安全,需进一步研究优化治疗策略。
要点
- CSEMS治疗MHBO的汇总技术成功率为96.7%(95%CI 92.6-98.6;I²=0%)。
- 汇总临床成功率为91.6%(95%CI 86.1-95.0;I²=0%)。
- 总体不良事件发生率为16.6%(95%CI 11.2-23.9;I²=24%),其中胆管炎7.4%、胰腺炎5.9%、肝脓肿5.9%、胆囊炎2.8%。
核心结论
- Meta分析显示CSEMS置入治疗MHBO的技术成功率和临床成功率高。
- 不良事件(尤其胆管炎、胆囊炎和胰腺炎)发生率<10%。
- RBO和支架移位可通过CSEMS取出和成功再干预得到缓解。
- 作者认为研究结果凸显CSEMS在MHBO管理中的疗效与安全性,需进一步研究以优化治疗策略。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE和Cochrane Library截至2024年3月31日。
- 从401篇文章中纳入7项研究,纳入标准为成人MHBO患者接受CSEMS置入并报告技术成功、临床成功和不良事件率的研究。
- 采用随机效应模型进行数据合成与统计分析,评估异质性和发表偏倚。
主要发现
- 汇总技术成功率为96.7%(95%CI 92.6-98.6;I²=0%)。
- 汇总临床成功率为91.6%(95%CI 86.1-95.0;I²=0%)。
- 总体不良事件发生率为16.6%(95%CI 11.2-23.9;I²=24%),包括胆管炎7.4%、胰腺炎5.9%、肝脓肿5.9%、胆囊炎2.8%。
- 支架移位和RBO分别见于8.9%和49.6%的病例,中位RBO时间为142天。
- 再干预成功率为92.5%(95%CI 83.1-96.9;I²=0%)。
关键数值与推荐
- 技术成功定义及判定标准见原文纳入研究。
- 临床成功定义及判定标准见原文纳入研究。
- 不良事件包括胆管炎、胰腺炎、肝脓肿、胆囊炎、支架移位和RBO。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在结论中提出需进一步研究以优化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Covered self-expandable metal stents (CSEMSs) are used for malignant hilar biliary obstruction (MHBO) management. Despite increasing evidence, a comprehensive evaluation of the efficacy and safety of CSEMSs in MHBO management is lacking. METHODS: PubMed, EMBASE, and the Cochrane Library were screened up to March 31, 2024, for studies including MHBO treated by a CSEMS. Studies meeting predefined inclusion criteria, including adult MHBO patients treated with CSEMS placement, reporting technical success, clinical success, and adverse event rates were selected. Data synthesis and statistical analysis were performed using the random-effects model, with heterogeneity and publication bias assessment. RESULTS: From 401 articles, 7 studies were included. Pooled technical and clinical success rates of CSEMSs were 96.7% (95% confidence interval [CI], 92.6-98.6; I2 = 0%) and 91.6% (95% CI, 86.1-95.0; I2 = 0%). Overall adverse events were reported in 16.6% of cases (95% CI, 11.2-23.9; I2 = 24%), which included cholangitis (7.4%), pancreatitis (5.9%), liver abscess (5.9%), and cholecystitis (2.8%). Stent migration and recurrent biliary obstruction (RBO) were observed in 8.9% and 49.6% of cases, respectively, with a median time to RBO of 142 days. Reintervention was successful in 92.5% of cases (95% CI, 83.1-96.9; I2 = 0%). CONCLUSIONS: Our meta-analysis revealed high technical and clinical success rates of CSEMS placement in MHBO. Adverse events, notably cholangitis, cholecystitis, and pancreatitis, were <10%. RBO and stent migration were mitigated by CSEMS removal and successful reintervention. Our findings highlight the efficacy and safety of CSEMSs in managing MHBO, warranting further research to optimize treatment strategies.
引用
- Chung KH, Lee KJ, Joseph AA, et al. Efficacy and safety of covered self-expandable metal stents for malignant hilar biliary obstruction: systematic review and meta-analysis. Gastrointest Endosc. 2024. PMID: 39357660. doi:10.1016/j.gie.2024.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。